<DOC>
	<DOCNO>NCT00756730</DOCNO>
	<brief_summary>For participant HIV take either lopinavir fosamprenavir elevate triglyceride , trial study change triglyceride switch protease inhibitor .</brief_summary>
	<brief_title>Lopinavir/r Fosamprenavir/r Switch Atazanavir/r Darunavir/r</brief_title>
	<detailed_description>This Phase IV trial look lipid virologic response switch lipid-friendly antiretroviral regimen . Participants randomize receive either boost atazanavir boost darunavir give daily , along background NRTIs . This 24-week study require 4 visit randomization evaluation , monitoring , lab study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Benzocaine</mesh_term>
	<criteria>Currently receive Antiretroviral Therapy ( ART ) regimen include LPV/r FPV/r &gt; equal 2 Nucleoside Reverse Transcriptase Inhibitors ( NRTIs ) . Patient must stable regimen contain LPV/r FPV/r least 12 week prior screen . Documentation undetectable Human Immunodeficiency Virus ( HIV ) viral load ( VL &lt; 400 copies/ml ) use FDA approve assay minimum twelve week prior screen AND undetectable HIV viral load use FDA approve ultrasensitive assay screening . No evidence HIV protease resistance define Stanford HIV database Currently receive first protease inhibitor unless switch LPV/r FPV/r nonvirologic reason Fasting triglyceride &gt; 200 mg/dL No ongoing issue opinion investigator would lead decreased ability comply study procedure If currently receive proton pump inhibitor , dose &lt; omeprazole 20 mg equivalent dose another proton pump inhibitor If patient receive another lipid lower medication , must stable dose Currently receive ART regimen &gt; equal two NRTIs either LPV/r FPV/r Prior use darunavir atazanavir CDC Class C Illness diagnose within 30 day screen Patient currently receive follow HydroxamethylglutarylcoA ( HMGCoA ) reductase inhibitor medication ( statin ) : pravastatin , lovastatin , simvastatin Patient currently receive bile acid sequestrant ( cholestyramine , colestipol , colesevelam ) Grade 3 4 Laboratory abnormality define standardized grade scheme base DAIDS table follow exception : 1 . Preexisting diabetes mellitus asymptomatic , nonfasting glucose grade 3 elevation 2 . Subjects asymptomatic grade 3 fast triglyceride cholesterol elevation Clinical laboratory evidence clinically significant liver impairment/dysfunction disease cirrhosis Note : Individuals coinfected chronic hepatitis B C viruses allow enter trial condition clinically stable require therapy course study . Individuals diagnose acute viral hepatitis screening allow enroll acute phase Active substance abuse significant psychiatric illness opinion investigator might interfere study compliance Use investigational agent 30 day prior screen Life expectancy &lt; 6 month opinion investigator Pregnancy breast feed Female subject childbearing potential ( i.e. , heterosexually active , surgically sterile least two year postmenopausal ) use effective nonhormonal birth control method willing continue practice birth control method screen last trial relate activity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>lopinavir</keyword>
	<keyword>ritonavir</keyword>
	<keyword>atazanavir</keyword>
	<keyword>fosamprenavir</keyword>
	<keyword>darunavir</keyword>
	<keyword>anti-retroviral</keyword>
	<keyword>AIDS</keyword>
	<keyword>HIV</keyword>
	<keyword>LARD</keyword>
	<keyword>triglyceride</keyword>
	<keyword>protease inhibitor</keyword>
	<keyword>treatment Experienced</keyword>
</DOC>